Ajanta Pharma has published the written transcript of its earnings call for the first quarter of FY27 (Q1FY27), providing investors with a detailed textual record of management’s discussion on the quarter ended June 30, 2026. The conference call was originally held on July 30, 2026, at 4:15 p.m., and the transcript complements the audio recording previously released by the company. This disclosure ensures that all stakeholders have access to the specific questions raised by analysts and the precise responses provided by executive leadership regarding financial performance and strategic outlook.

The filing was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, which mandates listed entities to provide access to earnings call materials to ensure transparency and equal information dissemination. The transcript is hosted directly on the company’s investor relations portal and was simultaneously dispatched to both the BSE Limited and the National Stock Exchange of India on August 3, 2026.

Accessing the Transcript

Investors can review the complete text of the proceedings through the official link provided in the exchange filing. The document covers the entire duration of the call, including management presentations and the question-and-answer session.

Regulatory Compliance and Sign-off

The disclosure was signed by Gaurang Chinubhai Shah, Senior Vice President – Legal & Company Secretary at Ajanta Pharma. The digital signature confirms the authenticity of the document, dated August 3, 2026, at 16:09:57 +05'30'. This step completes the regulatory requirement for post-call documentation, following the initial release of the audio recording.

Analytical Context

While the transcript itself contains the raw data of management’s commentary, its publication allows for a more granular analysis of the company’s guidance and operational updates compared to audio-only reviews. Investors can now cross-reference specific statements on revenue drivers, margin pressures, or pipeline developments with the financial figures reported in the quarterly results. The availability of both audio and text formats underscores Ajanta Pharma’s commitment to regulatory compliance and investor accessibility.

Ajanta Pharma reported a consolidated net profit of ₹334.22 crore for the quarter ended June 30, 2026, marking a 30.9% year-on-year increase from ₹255.34 crore in Q1FY26. The growth was primarily driven by a 57% surge in US Generic revenues to ₹487 crore and robust performance in its India branded generics segment, which grew 24% to ₹509 crore. Total consolidated revenue from operations rose 24.8% to ₹1,625.96 crore, reflecting strong operational momentum across key therapeutic areas including cardiology, ophthalmology, and dermatology. Shareholders will receive an interim dividend of ₹32 per share, with payments scheduled on or after August 18, 2026.

The Board of Directors approved the unaudited financial results at its meeting held on July 30, 2026, in compliance with Regulations 33, 42, and 43 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Alongside the results, the Board declared a first interim dividend of ₹400 crore for financial year 2027, translating to ₹32 per share on the face value of ₹2 per share. The record date for dividend payment is fixed at August 5, 2026. Statutory auditors M/s B S R & Co. LLP issued limited review reports on both consolidated and standalone financial results.

Financial Performance Overview

Consolidated earnings before tax stood at ₹446.80 crore, compared to ₹331.13 crore in Q1FY26. Adjusted EBITDA (excluding forex loss) increased 21% to ₹454 crore against ₹377 crore in the prior-year period, maintaining a margin of 28%. Standalone net profit after tax rose 23.7% to ₹315.47 crore from ₹254.97 crore in Q1FY26. Standalone revenue from operations increased 23.2% to ₹1,488.67 crore.

Earnings per share on a basic consolidated basis reached ₹26.72, up from ₹20.43 in Q1FY26. Return on Capital Employed (ROCE) stood at 37%, while Return on Net Worth (RONW) was 28%. Research and development expenses rose to ₹66 crore, representing 4% of revenue.

Segment-Wise Growth Drivers

The company’s diversified portfolio delivered varied growth rates across geographies. The Africa Institution business saw an 83% jump to ₹70 crore from ₹38 crore. In contrast, Asia branded generics declined 16% to ₹255 crore from ₹304 crore, likely due to market-specific dynamics. Overall, branded generics sub-total grew 13% to ₹1,059 crore.

In India, Ajanta Pharma’s branded generic performance exceeded the Indian Pharmaceutical Market (IPM) growth by 36% as per IQVIA MAT June 2026 data. New launches outperformed IPM by 76%, while volumes exceeded IPM by 40%. Key therapy segments such as Ophthalmology (15% vs 10% IPM), Dermatology (14% vs 8% IPM), and Pain Management (15% vs 10% IPM) contributed significantly to this outperformance.

Regulatory and Operational Updates

Ajanta Pharma continues to strengthen its US pipeline, with 51 ANDAs commercialized as of Q1FY27. The company received three new approvals and launched two products during the quarter. Currently, 17 applications await approval with the US FDA, and five hold tentative approval status.

Regarding regulatory matters, the company noted that Income Tax Authorities carried out search operations in August 2025. The company filed returns for the block period from April 1, 2019, to November 17, 2025, on April 6, 2026. Management stated that the consequent impact on consolidated financial results for the quarter ended June 30, 2026, is currently not ascertainable pending further communication from authorities.

What the Numbers Show

The divergence between revenue growth (24.8%) and profit growth (30.9%) indicates an expansion in operating margins during the quarter. With adjusted EBITDA margins holding steady at 28% despite higher forex volatility (foreign exchange gain of ₹50.47 crore offset by loss of ₹30.59 crore), the company demonstrates resilient cost management. The substantial interim dividend payout of ₹400 crore underscores management’s confidence in cash flow generation capabilities for the remainder of FY27.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE031B01049/1be40f2ef982457c.pdf